U.S. Markets open in 2 hrs 11 mins

RedHill Biopharma Ltd. (RDHL)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
0.8821-0.1379 (-13.52%)
At close: 04:00PM EDT
0.8987 +0.02 (+1.88%)
Pre-Market: 07:16AM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.0200
Bid0.0000 x 1300
Ask0.0000 x 1300
Day's Range0.8700 - 1.0200
52 Week Range0.6200 - 11.1800
Avg. Volume2,013,325
Market Cap46.223M
Beta (5Y Monthly)1.79
PE Ratio (TTM)N/A
EPS (TTM)-2.2410
Earnings DateMar 16, 2022 - Mar 21, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.38
  • American City Business Journals

    Raleigh drugmaker slashes workforce as biotech downturn deepens

    The drugmaker is cutting one-third of its U.S. commercial workforce as part of a plan to save $50 million. The move comes as the biotech industry sees cuts across the board as the highs of the pandemic fade away.

  • Benzinga

    RedHill Biopharma Shares Trading Higher On Improved Q1 Profitability

    View more earnings on RDHLSee more from BenzingaThe Daily Biotech Pulse: F-Star Therapeutics Buyout, Orphan Drug Tag For VBI's Brain Cancer Vaccine, Xenon's Epilepsy Candidate Shows PromiseDon't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.© 2022 Benzinga does not provide investment advice. All rights reserved.

  • PR Newswire

    RedHill Biopharma Announces Q1/22 Highlights: On Track for Positive Cash from Operations in H2/22

    RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today reported its first quarter 2022 financial results and operational highlights, targeting positive cash from operations1 to start during H2/22 and recent implementation of a comprehensive cost reduction plan, expected to generate operational cost savings of approximately $50 million over the next 18 months.